Keisuke Onoi, Tadaaki Yamada, Kenji Morimoto, Hayato Kawachi, Rei Tsutsumi, Takayuki Takeda, Asuka Okada, Nobuyo Tamiya, Yusuke Chihara, Shinsuke Shiotsu, et al. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients. Targeted oncology. 2024
Masaki Ishida, Masahiro Iwasaku, Toshifumi Doi, Takeshi Ishikawa, Yusuke Tachibana, Ryo Sawada, Yuri Ogura, Hayato Kawachi, Yuki Katayama, Naoya Nishioka, et al. Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer. Cancer science. 2024
Yuki Katayama, Tadaaki Yamada, Kenji Morimoto, Hiroyuki Fujii, Satomi Morita, Keiko Tanimura, Takayuki Takeda, Asuka Okada, Shinsuke Shiotsu, Yusuke Chihara, et al. Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study. JTO clinical and research reports. 2024. 5. 3. 100644-100644
Yuki Katayama, Tadaaki Yamada, Ryo Sawada, Hayato Kawachi, Kenji Morimoto, Satoshi Watanabe, Kageaki Watanabe, Takayuki Takeda, Yusuke Chihara, Shinsuke Shiotsu, et al. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer. The oncologist. 2024
Kenji Morimoto, Tadaaki Yamada, Hayato Kawachi, Motohiro Tamiya, Yoshiki Negi, Yasuhiro Goto, Akira Nakao, Shinsuke Shiotsu, Keiko Tanimura, Takayuki Takeda, et al. Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status. Targeted oncology. 2023. 18. 6. 915-925